Racial Differences in the Prognosis and Survival of Cutaneous Melanoma From 1990 to 2020 in North America: A Systematic Review and Meta-Analysis

Megan Lam1, Jie Wei Zhu1, Angie Hu2, and Jennifer Beecker3,4,5,6

Abstract

Background: Factors influencing the difference in the diagnosis and treatment of melanoma in racial minority groups are well-described in the literature and include atypical presentations and socioeconomic factors that impede access to care.

Objective: To characterize the differences in melanoma survival outcomes between non-Hispanic white patients and ethnic minority patients in North America.

Methods: We conducted searches of Embase via Ovid and MEDLINE via Ovid of studies published from 1989 to August 5, 2020. We included observational studies in North America which reported crude or effect estimate data on patient survival with cutaneous melanoma stratified by race.

Results: Forty-four studies met our inclusion criteria and were included in this systematic review. Pooled analysis revealed that black patients were at a significantly increased risk for overall mortality (HR 1.42, 95% CI, 1.25-1.60), as well as for melanoma-specific mortality (HR 1.27, 95% CI, 1.03-1.56). Pooled analyses using a representative study for each database yielded similar trends. Other ethnic minorities were also more likely report lower melanoma-specific survival compared to non-Hispanic white patients.

Conclusion: Our results support findings that melanoma patients of ethnic minorities, particularly black patients, experience worse health outcomes with regards to mortality. Overall survival and melanoma-specific survival are significantly decreased in black patients compared to non-Hispanic white patients. With the advent of more effective, contemporary treatments such as immunotherapy, our review identifies a gap in the literature investigating present-day or prospective data on melanoma outcomes, in order to characterize how current racial differences compare to findings from previous decades.

Keywords
melanoma, socioeconomic, race, survival, prognosis

Introduction

While the incidence of cutaneous melanoma in minority populations are reported to be lower than in non-Hispanic white populations, age-adjusted incidence rates of cutaneous melanoma of all stages are increasing.1,2 Melanoma accounts for approximately 75% of skin cancer deaths, and early detection plays an important role in reducing mortality risk.3 Several studies have identified disparities in the diagnosis and treatment of melanoma in racial minority patients compared to non-Hispanic white patients,4-6 and the presentation of cutaneous melanoma in minority groups is more frequently characterized as atypical in general appearance, location, and histologic subtype.6 Socioeconomic disparities that disproportionately affect black populations, including residing in lower socioeconomic status neighborhoods and being uninsured, are associated with later stage at cancer diagnosis and a greater risk of death.7-10 We conducted this

1Faculty of Medicine, Michael G. DeGroote School of Medicine, Hamilton, ON, Canada
2Faculty of Science, University of Calgary, AB, Canada
3Division of Dermatology, University of Ottawa, ON, Canada
4The Ottawa Hospital, ON, Canada
5Ottawa Research Institute, ON, Canada
6Probity Medical Research Inc., Waterloo, ON, Canada

Corresponding Author:
Jennifer Beecker, The Division of Dermatology, The Ottawa Hospital, 737 Parkdale Ave, 4th Floor, Parkdale Clinic, Ottawa, ON K1Y 4E9, Canada.
Email: jbeecker@toh.ca
systematic review and meta-analysis to assess and characterize the differences in melanoma survival outcomes between non-Hispanic white and black patients, as well as other ethnic minority groups.

**Material and Methods**

This systematic review was performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The protocol of this review was prospectively registered in the Prospective Register of Systematic Reviews (PROSPERO; CRD42020202891).

**Search Strategy**

We conducted a comprehensive search of Embase via Ovid and MEDLINE via Ovid on August 5, 2020. Our search strategy is comprised of key terms for race and socioeconomic factors, melanoma, and observational study designs, with guidance from an experienced librarian (Mendeley Supplemental Tables S1-S2). Our search was limited to human studies and English records, as well as studies published from 1989 to 2020, inclusive. Additionally, we manually searched citations of included studies and relevant review articles for additional studies not included in our original search.

**Study Selection and Data Abstraction**

We included observational studies (cohort, cross-sectional, or case-control studies) of melanoma patients which reported either (i) crude survival or mortality prevalence rates out of total patients with cutaneous melanoma, or (ii) effect estimate data on survival or mortality of cutaneous melanoma, stratified by more than one race or ethnicity. Studies conducted outside of North America were excluded, as stated previously. Additionally, we excluded studies that reported (i) only one race, (ii) insufficient data to determine the effect estimate, relative survival, or denominator for prevalence, or (iii) outcomes not specific to cutaneous melanoma patients.

All retrieved titles and abstracts were screened for relevance and full texts assessed for eligibility independently and in duplicate (pairs of M.L., J.Z., and A.H.). Discrepancies between reviewers were discussed until consensus was reached. The following data were extracted in duplicate (M.L. and J.Z.) from individual studies using a standardized form: study characteristics (author, year of publication, disease, funding, patient source, inclusion criteria), patients demographics (number of patients, race groups, age range), melanoma characteristics (tumor stage, Breslow thickness, local or distant metastasis, melanoma type), and outcomes (type of survival/mortality, no. of deaths, % survival, effect estimate, adjusted variables).

**Quality Assessment of Studies**

Risk of bias for included studies was assessed using the NIH National Heart Lung and Blood Institute Quality Assessment Tool for cohort and cross-sectional studies, and the Quality Assessment Tool for case-control studies was planned to be used but was not needed as there weren’t any case control studies included. A quality rating of good, fair, or poor was assigned independently by 2 reviewers (M.L. and J.Z.) based on a set of 14 criteria, and discrepancies were discussed until full consensus was reached.

**Statistical Analysis**

The proportions of studies reporting lower overall survival and melanoma-specific survival in ethnic minority patients were calculated. Random-effects inverse variance meta-analyses were performed where possible to generate pooled hazard ratios for risk of mortality for patients of ethnic minorities compared to non-Hispanic white patients. In the case where multiple studies drew from the same database of patients, only representative studies which drew patients from the longest length of time from their respective databases. Additionally, sub-analyses eliminating all studies using data from any national cancer database were performed to further reduce risk of double-counting patient data. Estimates reported from the most adjusted model were used when available. Statistical heterogeneity between studies were assessed using the $I^2$ statistic. All analyses were conducted using Review Manager version 5.3 (Cochrane Collaboration, Software Update, Oxford, United Kingdom). $P$ values of less than 0.05 were considered statistically significant.

**Results**

Our initial search yielded a total of 4906 records. Upon removal of 1220 duplicate records, 3686 records were screened based on titles and abstracts. From these, 368 records were assessed for full-text eligibility. We excluded 324 full-text records, including 102 records excluded due to irrelevant study design, 27 records for not examining outcomes specific to cutaneous melanoma, 70 records for not stratifying by race or only examining one race, and 77 records that did not examine outcomes of survival or mortality. Ultimately, 44 studies met our inclusion criteria and were included in this systematic review (Supplemental Figure S1).

Most studies were published from 2011 and onwards ($n = 35$), reported a public source of funding ($n = 19$), and used patient data drawn from national cancer databases ($n = 35$).
Eleven studies included adult patients exclusively and 2 studies included only pediatric patients. Most studies (26 studies) were assigned a quality assessment rating of “fair” and 11 studies were assigned a rating of “good”. The 7 studies assigned a “poor” rating were predominantly found to have insufficiently defined study populations, outcome measures, and confounding variables (Table 1).

Of the 44 studies included, there were a total of 3,168,108 patients. Thirty-seven studies included black patients (n = 2,357,800). With respect to study outcomes, 28 studies reported effect estimates for survival stratified by any race. 29 studies reported disease-specific survival/mortality, 20 studies reported overall survival/mortality, and 3 studies reported relative survival data.

### Outcomes for Black Patients Compared to Non-Hispanic White Patients

In total, 33 (75%) studies compared non-Hispanic white and black patient survival, with 27 of these studies reporting worse outcomes for black patients. Five studies reported AJCC cancer stages for black patients, with weighted mean % of patients at stage I (n = 501 patients, 52.6%), stage II (n = 223, 24.1%), stage III (n = 123, 16.3%), and stage IV (n = 101, 12.2%).

Seven studies comparing non-Hispanic white and black survival reported histological subtype stratified by race, with total patients and mean proportion of patients as follows: nodular melanoma (black: n = 1090, 10.0%; non-Hispanic white: n = 72029, 19.1%), lentigo maligna melanoma (n = 196, 3.7%; n = 75631, 7.6%), superficial spreading melanoma (n = 1611, 19.0%; n = 312754, 39.3%), and acral lentiginous melanoma (n = 2107, 19.4%; n = 8141, 0.99%).

The most common subtype reported in black patients were superficial spreading melanoma in 4 studies, and acral lentiginous melanoma in 3 studies, while superficial spreading melanoma was the most commonly reported subtype for non-Hispanic white patients among all 7 studies. Malignant melanoma with subtype not otherwise specified was reported in a greater proportion of black patients (n = 2825, 53.9%) than white patients (n = 483,065, 48.0%). Six studies reported the anatomic site of the primary melanoma, all of which reported the lower extremities as being the most common site for black patients and the trunk as the most common site for non-Hispanic white patients.

Of the 21 studies that reported effect estimates for mortality risk for black patients with non-Hispanic white patients as the reference group, 14 adjusted for cancer stage, 8 for histologic subtype, and 7 for anatomic site. Four studies adjusted for tumor thickness, while 3 studies adjusted for ulceration status. Socioeconomic status was included in adjustments in 7 studies, of which 4 reported adjusting for income specifically and 2 reported adjusting for education level (Table 2).

### Overall Survival for Black Patients Compared to Non-Hispanic White Patients

All 5 studies measuring overall survival percentages reported decreased survival for black patients compared to non-Hispanic white patients. However, one study reported significantly increased survival for black patients following adjustment for income (Supplemental Table S3).

Twelve studies reported effect estimates and confidence intervals for risk of mortality from any cause for black patients compared to non-Hispanic white patients. All

---

**Table 1. Overview of Study and Patient Characteristics for Studies Included in the Systematic Review.**

| Study characteristics | No. of studies (%) |
|-----------------------|--------------------|
| Year published        |                    |
| 1990–1994             | 1 (2)              |
| 1994–1999             | 1 (2)              |
| 2000–2004             | 1 (2)              |
| 2005–2009             | 5 (11)             |
| 2010–2014             | 10 (23)            |
| 2015–2020             | 26 (59)            |
| Funding               |                    |
| Public                | 19 (43)            |
| Public and private    | 2 (5)              |
| None                  | 6 (14)             |
| Not reported          | 17 (39)            |
| Patient source        |                    |
| National database     | 35 (80)            |
| SEER                  | 31 (70)            |
| NCDB                  | 4 (9)              |
| State registry data   | 4 (9)              |
| Hospital data         | 2 (5)              |
| Other database        | 3 (7)              |
| NIH Quality Assessment|                    |
| Good                  | 12 (27)            |
| Fair                  | 25 (57)            |
| Poor                  | 7 (16)             |
| Patient characteristics|                   |
| Minority groups       |                    |
| Black                 | 37 (84)            |
| Asian                 | 22 (50)            |
| Pacific islander      | 15 (34)            |
| NaBlacktive           | 13 (30)            |
| Hispanic              | 23 (52)            |
| Age range             |                    |
| Adult only            | 11 (25)            |
| Peds                  | 2 (5)              |
| Both                  | 5 (11)             |
| NR                    | 26 (59)            |

*aOut of the 44 included studies.*
studies reported an increased risk of death for black patients. Pooled analysis of effect estimates of all studies resulted in a significantly increased risk of mortality from any cause for black patients, with a pooled HR of 1.42 (95% CI, 1.25-1.60). As multiple studies drew patient data from the same database, we pooled effect estimates from a representative study from each database with the longest timeframe from which patient data were drawn (HR 1.38, 95% CI, 1.10-1.73) (Figure 1).2,6,28,52 We also performed sensitivity analyses removing any studies using patient data from the Surveillance, Epidemiology, and End Results (SEER) program database (HR 1.29, 95% CI, 1.07-1.56),6,28,53,52 and removing any studies with patient data from any national cancer database (HR 1.62, 95% CI, 1.20-2.19).6,52 Overall, results of our meta-analyses suggest that black melanoma patients are significantly more likely to experience death from any cause compared to non-Hispanic white patients.

Melanoma-Specific Survival for Black Patients Compared to Non-Hispanic White Patients

Twelve studies reported melanoma-specific survival percentages,2,15,20,29,32,34,36,45,50,51 and among the 11 studies reporting 5-year survival, 9 studies reported decreased survival for black patients. Of the 3 studies reporting 10-year survival, 1 study reported decreased survival for black patients (Supplemental Table S3).

Thirteen studies reported effect estimates for risk of melanoma-specific death for black patients compared to non-Hispanic white patients, of which 4 studies reported a decreased risk of melanoma-specific mortality for black patients.2,31,41,43 Collins et al. reported that while black patients experienced a significantly increased risk of melanoma-specific death upon receiving surgical treatment, black patients also experienced a decreased risk of death in the nonsurgical treatment group, although this association was not statistically significant.2 Similarly, Jemal et al. reported a nonsignificant decreased risk of melanoma-specific death for black male patients, but a significantly increased risk of melanoma-specific death for black female patients, compared to female non-Hispanic white patients.31 Ward-Peterson reported a significantly decreased melanoma-specific mortality risk for black patients compared to non-Hispanic white patients (HR 0.7, 95% CI, 0.6-0.8, P < .001) in the most adjusted model that accounted for both site and stage at diagnosis.43

Pooled analysis of effect estimates from all studies revealed a significantly increased risk of melanoma-specific mortality for black patients, with a pooled HR of 1.27 (95% CI, 1.03-1.56). Using a representative study from each database also found a stronger association (HR 1.45, 95% CI, 1.01-2.07) (Figure 2).2,6,52 Following removal of studies with data from any national cancer database, we observed a stronger association between melanoma-specific mortality and black patients (HR 2.04, 95% CI, 1.35-3.07).6,52 Our results support an overall increased melanoma-specific mortality in black patients compared to non-Hispanic white patients.
Melanoma-Specific Survival for Other Ethnic Minorities Compared to Non-Hispanic White Patients

Twenty-three studies reported 62505 Hispanic patients,4,6,10,15,19-22,24,25,27,30,31,36-38,43-45,50-53 with 10 studies reporting melanoma-specific survival,4,15,19,20,30,31,36,45,50,53 where all but 2 studies50,53 reported lower survival for Hispanic patients compared to non-Hispanic white patients.

Twenty-one studies included Asian patients,4,6,10,15,19-22,30,31,36-39,41,42,44,45,50,52,53 with 17 of these studies combining patients of Asian and Pacific Islander race into 1 subgroup, to a total of 18878 Asian and Pacific Islander patients. Ten studies reported melanoma-specific survival,4,15,20,30,31,36,45,50,53 with all but 2 studies50,53 reporting lower survival for Asian and Pacific Islander patients compared to non-Hispanic white patients.

Thirteen studies included American Indian patients,4,20,21,30,31,36-38,41,42,44,45,53 with 9 studies also including Alaskan Native patients in this group, to a total of 2239 patients. Seven studies reported melanoma-specific survival for American Indian and Alaskan Native patients,4,20,30,31,36,45,53 with only 1 study reporting higher survival in American Indian or Alaskan Native patients compared to non-Hispanic patients.53

There was insufficient data to pool effect estimates using a representative study from each database for these ethnic minority groups.

Discussion

A total of 44 studies were included, of which 33 studies compared survival or mortality outcomes for black patients with those of non-Hispanic white melanoma patients. Pooled analyses indicate a statistically significant difference, with decreased overall survival and melanoma-specific survival for black patients. Melanoma-specific survival for other ethnic minorities was also more frequently reported as lower compared to non-Hispanic white patients. A gap in the present literature exists where more recent studies omit an updated examination of current disparities compared to findings from previous decades.

Reduced overall survival for ethnic minority patients compared to non-Hispanic white patients may be attributed to several contributing factors. First, a longer time to diagnosis and subsequently a diagnosis at more advanced stages can lead to a poorer prognosis.4,19,54,55 A study of over 100,000 patients by Dick et al. found black patients were significantly more likely to present with advanced-stage disease, even after adjusting for tumor characteristics and patient demographic factors.56 A recent retrospective review from the National Cancer Database also showed that black patients had longer time from diagnosis to definitive surgery, which also might influence survival.57 Second, socioeconomic status differences may lead to increased barriers that limit access to medical care in minority populations. Communities of lower socioeconomic status also tend to have a decreased density of dermatologists, further reducing access to care.58 Third, acral lentiginous melanoma comprises a higher proportion of total melanoma in patients of black, Hispanic, and Asian race. This subtype is associated with increased tumor thickness and more advanced stage at presentation,15,59,60 and in our analyses we found that black patients were more likely to present with acral lentiginous melanoma (19.4%) compared to white patients (0.99%). Black patients were also more likely to be reported as having a malignant melanoma of unspecified subtype compared to non-Hispanic white patients. Genetic differences may cause melanoma tumors to present more aggressively or nontraditionally in certain populations.

Unfortunately, many of the studies published more recently however continued to use retrospective patient data prior to 2011, which obscures trends in how racial disparities have changed over time. With the advent of more effective, contemporary treatments such as immunotherapy, it will be important to examine how racial differences in outcomes in North America are affected. The study by Haque et al. highlights that while immunotherapy was associated with improved overall survival, African American patients were less likely to receive immunotherapy.28 Interestingly, the study by Al-Qurayshi et al. in 2018 found no statistically significant racial differences in immunotherapy usage, but rather, that those without private insurance translated into worse outcomes in mortality, and seemed to be a more significant contributing factor.51 Recent decades have also seem the implementation of various measures to improve health outcomes and access to healthcare.
for marginalized groups including increased education around the presentation of common skin conditions in ethnic skin types and a greater inclusion of articles on skin of color.61-63 However, overall inclusion is still low and darker skin types are still underrepresented in mainstream dermatology textbooks and educational materials.64,65 Ultimately, health outcomes for melanoma patients of racial backgrounds need to be revisited with a modern lens in order to better characterize current racial differences in outcomes.

Limitations

Our study had several limitations. Our review was limited to studies conducted in North America, with the large majority of studies from the United States, and while this reduced heterogeneity of sociocultural factors, studies from other multi-cultural countries outside of North America offer important insight that may be applicable to the general population. Additionally, although we performed sensitivity analyses to remove studies using data from national cancer databases, pooled effect estimates may be exaggerated as the majority of studies that were included in this review used patient data from the SEER database. It must also be mentioned that the definitions of black and non-Hispanic white are open to subjectivity, and may differ between or even within studies. Lastly, most of the included studies were based on patient data obtained from national-level cancer databases. Sixteen percent of included studies were assigned a rating of “poor” during quality assessment, largely due to the limited nature of retrospective database analysis, and limited population description and justification.

Conclusion

Overall, our results suggest that differences in health outcomes for ethnic minority melanoma patients, particularly black patients, continue to exist. While studies included in this review reported mortality among patients diagnosed with melanoma, additional large-scale epidemiological studies to better estimate case fatality rate will be valuable. Our review identified a paucity of literature investigating present-day or prospective data on melanoma outcomes, and as patients receive more effective, contemporary treatments, it will be important to continue to examine how healthcare professionals can seek to improve outcomes and reduce barriers to care for marginalized populations.

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

ORCID iD

Megan Lam  https://orcid.org/0000-0001-5819-7684

Supplemental Material

Supplemental material for this article is available online.

References

1. SEER Cancer statistics review, 1975-2007. National Institutes of Health. Published 2010. Accessed October 16, 2020. https://seer.cancer.gov/archive/csr/1975_2007/
2. Collins KK, Fields RC, Baptiste D, Liu Y, Moley J, Jeffe DB. Racial differences in survival after surgical treatment for melanoma. Ann Surg Oncol. 2011;18(10):2925-2936. doi:10.1245/s10434-011-1706-3
3. Xavier MHSB, Drummond-Lage AP, Baeta C, Rocha L, Almeida AM, Wainstein AJA. Delay in cutaneous melanoma diagnosis: sequence analyses from suspicion to diagnosis in 211 patients. Medicine. 2016;95(31):e4396. doi:10.1097/MD.0000000000004396
4. Cormier JN, Xing Y, Ding M, et al. Ethnic differences among patients with cutaneous melanoma. Arch Intern Med. 2006;166(17):1907-1914. doi:10.1001/archinte.166.17.1907
5. Hemmings DE. Cutaneous melanoma in a multiethnic population. Arch Surg. 2004;139(9):968. doi:10.1001/archsurg.139.9.968
6. Zell JA, Cinar P, Mobasher M, Ziegas A, Meyskens FL, Anton-Culver H. Survival for patients with invasive cutaneous melanoma among ethnic groups: the effects of socioeconomic status and treatment. J Clin Oncol. 2008;26(1):66-75. doi:10.1200/JCO.2007.12.3604
7. Aizer AA, Falit B, Mendu ML, et al. Cancer-specific outcomes among young adults without health insurance. J Clin Oncol. 2014;32(19):2025-2030. doi:10.1200/JCO.2013.54.2555
8. Robbins AS, Lerro CC, Barr RD. Insurance status and distant-stage disease at diagnosis among adolescent and young adult patients with cancer aged 15 to 39 years: National cancer data base, 2004 through 2010. Cancer. 2014;120(8):1212-1219. doi:10.1002/cncr.28568
9. Rosenberg AR, Kroon L, Chen L, Li CI, Jones B. Insurance status and risk of cancer mortality among adolescents and young adults. Cancer. 2015;121(8):1279-1286. doi:10.1002/cncr.29187
10. DeRouen MC, Parsons HM, Kent EE, Pollock BH, Keegan THM. Sociodemographic disparities in survival for adolescents and young adults with cancer differ by health insurance status. Cancer Causes Control. 2017;28(8):841-851. doi:10.1007/s10552-017-0913-y
11. Karanth S, Fowler ME, Mao X, et al. Race, socioeconomic status, and health-care access disparities in ovarian cancer treatment and mortality: systematic review and meta-analysis. JNCI Cancer Spectr. 2019;3(4):1-11. doi:10.1093/jncics/pkz084
12. Terplan M, Smith EJ, Temkin SM. Race in ovarian cancer treatment and survival: a systematic review with meta-analysis. Cancer Causes Control. 2009;20(7):1139-1150. doi:10.1007/s10552-009-9322-2
13. Rich NE, Oji S, Mufti AR, et al. Racial and ethnic disparities in nonalcoholic fatty liver disease prevalence, severity, and outcomes in the United States: a systematic review and meta-analysis. *Clin Gastroenterol Hepatol*. 2018;16(2):198-210. doi:10.1016/j.cgh.2017.09.041

14. Berkman AM, Brewster AM, Jones LW, et al. Racial differences in 20-year cardiovascular mortality risk among childhood and young adult cancer survivors. *J Adolesc Young Adult Oncol*. 2017;6(3):414-421. doi:10.1089/jayo.2017.0024

15. Bradford PT, Goldstein AM, McMastel ML, Tucker MA. Acral lentiginous melanoma. *Arch Dermatol*. 2009;145(4):427-434. doi:10.1001/archdermatol.2008.609

16. Chang AE, Karnell LH, Menck HR. The national cancer data base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. *Cancer*. 1998;83(8):1664-1678.

17. Che G, Huang B, Xie Z, et al. Trends in incidence and survival in patients with melanoma, 1974-2013. *Am J Cancer Res*. 2019;9(7):1396-1414. http://www.ncbi.nlm.nih.gov/pubmed/31392077#0Ahttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC6682720

18. Culp MB, Lunsford NB. Melanoma among non-Hispanic black Americans. *Prev Chronic Dis*. 2019;16(6):1-8. doi:10.5888/pcd16.180640

19. Dawes SM, Tsai S, Gittleman H, Barnholtz-Sloan JS, Bordeaux JS. Racial disparities in melanoma survival. *J Am Acad Dermatol*. 2016;75(5):983-991. doi:10.1016/j.jaad.2016.06.006

20. Forjaz de Lacerda G, Howlader N, Mariotto AB. Differences in survival in cancer with relative versus cause-specific approaches: an update using more accurate life tables. *Cancer Epidemiol Biomarkers Prev*. 2019;28(9):1544-1551. doi:10.1158/1055-9965.EPI-19-0125

21. Du XL, Lin CC, Johnson NJ, Altekruse S. Effects of individual-level socioeconomic factors on racial disparities in cancer treatment and survival. *Cancer*. 2011;117(14):3242-3251. doi:10.1002/cncr.25854

22. Enewold L, Sharon E, Harlan LC. Metastatic melanoma: treatment and survival in the US after the introduction of ipilimumab and vemurafenib. *Oncol Res Treat*. 2017;40(4):174-183. doi:10.1159/000456014

23. Ezaldein, B.S. HH, Grunseich, B.A. K, Jairam, B.S. V, Ventura, M.D. A. Income-associated discrepancies in melanoma survival. *Cancer Treat Commun*. 2015;4(1):143-147. doi:10.1016/j.ctrc.2015.08.008

24. Feigelson HS, Powers JD, Kumar M, Carroll NM, Pathy A, Ritzwoller DP. Melanoma incidence, recurrence, and mortality in an integrated healthcare system: a retrospective cohort study. *Cancer Med*. 2019;8(9):4508-4516. doi:10.1002/cam4.2252

25. Feun LG, Raub WA, Duncan RC, et al. Melanoma in a southeastern Hispanic population. *Cancer Detect Prev*. 1994;18(2):145-152.

26. Garrett GL, Lowenstein SE, Singer JP, He SY, Arron ST. Trends of skin cancer mortality after transplantation in the United States: 1987 to 2013. *J Am Acad Dermatol*. 2016;75(1):106-112. doi:10.1016/j.jaad.2016.02.1155

27. Hamilton EC, Nguyen HT, Chang Y-C, et al. Health disparities influence childhood melanoma stage at diagnosis and outcome. *J Pediatr*. 2016;175:182-187. doi:10.1016/j.jpeds.2016.04.068

28. Haque W, Verma V, Butler EB, Teh BS. Racial and socioeconomic disparities in the delivery of immunotherapy for metastatic melanoma in the United States. *J Immunother*. 2019;42(6):228-235. doi:10.1097/CJI.0000000000000264

29. Hu C-Y, Xing Y, Cormier JN, Chang GJ. Assessing the utility of cancer-registry-processed cause of death in calculating cancer-specific survival. *Cancer*. 2013;119(10):1900-1907. doi:10.1002/cncr.27968

30. Jemal A, Ward EM, Johnson CJ, et al. Annual report to the nation on the status of cancer, 1975-2014, featuring survival. *J Natl Cancer Inst*. 2017;109(9):1-22. doi:10.1093/jnci/djx030

31. Jemal A, Clegg LX, Ward E, et al. Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival. *Cancer*. 2004;101(1):3-27. doi:10.1002/cncr.20288

32. Kachare SD, Brinkley J, Wong JH, Vohra NA, Zervas EE, Fitzgerald TL. The influence of sentinel lymph node biopsy on survival for intermediate-thickness melanoma. *Ann Surg Oncol*. 2014;21(11):3377-3385. doi:10.1245/s10434-014-3954-5

33. Lam PH, Obirieze AC, Ortega G, et al. An age-Based analysis of pediatric melanoma: staging, surgery, and mortality in the surveillance, epidemiology, and end results database. *Am Surg*. 2018;84(5):739-745. doi:10.1177/000313481808400528

34. Mahendra Raj K, Sidhu K, Lau CSM, McRoy GJ, Chamberlin RS, Smith FO. Malignant melanoma in African-Americans. *Medicine*. 2017;96(15):e6258. doi:10.1097/MD.0000000000006258

35. Merrill RM, Bateman S. Conditional melanoma cancer survival in the United States. *Cancers*. 2016;8(2):20.10.3390/cancers8020020 02 02 2016.

36. Pollack LA, Li J, Berkowitz Z, et al. Melanoma survival in the United States, 1992 to 2005. *J Am Acad Dermatol*. 2011;65(5 Suppl 1):S78.e1-S78.e10. doi:10.1016/j.jaad.2011.05.030

37. Reyes-Ortiz CA, Goodwin JS, Freeman JL, Kuo Y-F. Socioeconomic status and survival in older patients with melanoma. *J Am Geriatr Soc*. 2006;54(11):1758-1764. doi:10.1111/j.1532-5415.2006.00943.x

38. Shaikh WR, Dusza SW, Weinstock MA, Oliveria SA, Geller AC, Halpern AC. Melanoma thickness and survival trends in the United States, 1989–2009. *J Natl Cancer Inst*. 2016;108(1):1-7. doi:10.1093/jnci/djv294

39. Shin S, Palis BE, Phillips JL, Stewart AK, Perry RR. Cutaneous melanoma in Asian-Americans. *J Surg Oncol*. 2009;99(2):114-118. doi:10.1002/jso.21195

40. Singh P, Kim HJ, Schwartz RA. Superficial spreading melanoma: an analysis of 97 702 cases using the SEER database. *Melanoma Res*. 2016;26(4):395-400. doi:10.1097/CMR.0000000000000245
41. Stokes WA, Lentsch EJ. Age is an independent poor prognostic factor in cutaneous head and neck melanoma. Laryngoscope. 2014;124(2):462-465. doi:10.1002/lary.24315

42. Trofymenko O, Bordeaux JS, Zeitouni NC. Melanoma of the face and Mohs micrographic surgery: nationwide mortality data analysis. Dermatol Surg. 2018;44(4):481-492. doi:10.1097/DSS.0000000000001429

43. Ward-Peterson M, Acuña JM, Alkhalifah MK, et al. Association between Race/Ethnicity and survival of melanoma patients in the United States over 3 decades: a secondary analysis of SEER data. Medicine. 2016;95(17):e3315-3316. doi:10.1097/MD.0000000000003135

44. Abdel-Rahman O. Prognostic impact of socioeconomic status among patients with malignant melanoma of the skin: a population-based study. J Dermatol Treat. 2020;31(6):571-575. doi:10.1080/09546634.2019.1657223

45. Wu X-C, Eide MJ, King J, et al. Racial and ethnic variations in incidence and survival of cutaneous melanoma in the United States, 1999-2006. J Am Acad Dermatol. 2011;65(5 Suppl 1):S26.e1-S26.e13. doi:10.1016/j.jaad.2011.05.034

46. Xing Y, Chang GJ, Hu C-Y, et al. Conditional survival estimates improve over time for patients with advanced melanoma: results from a population-based analysis. Cancer. 2010;116(9):2234-2241. doi:10.1002/cncr.24966

47. Yang GB, Barnholtz-Sloan JS, Chen Y, Bordeaux JS. Risk and survival of cutaneous melanoma diagnosed subsequent to a previous cancer. Arch Dermatol. 2011;147(12):1395-1402. doi:10.1001/archdermatol.2011.1133

48. Mert I, Semaan A, Winer I, Morris RT, Ali-Fehmi R. Vulvar/vaginal melanoma: an updated surveillance epidemiology and end results database review, comparison with cutaneous melanoma and significance of racial disparities. Int J Gynecol Cancer. 2013;23(6):1118-1125. doi:10.1097/IGC.0b013e31829800fb

49. Afinasiev OK, Tu JH, Chu DH, Swetter SM. Characteristics of melanoma in white and nonwhite children, adolescents, and young adults: analysis of a pediatric melanoma institutional registry, 1995-2018. Pediatr Dermatol. 2019;36(4):448-454. doi:10.1111/pde.13836

50. Allan BJ, Ovadia S, Tashiro J, Thaller SR. Superficial spreading melanomas in children: an analysis of outcomes using the surveillance, epidemiology, and end results (SEER) database. Ann Plast Surg. 2015;75(3):327-331. doi:10.1097/SAP.0000000000001414

51. Al-Quarayshi Z, Crowther JE, Hamner JB, Ducoin C, Kilacky MT, Kandil E. Disparities of immunotherapy utilization in patients with stage III cutaneous melanoma: a national perspective. Anticancer Res. 2018;38(5):2897-2901. doi:10.21873/anticancerres.12536

52. Asgari MM, Shen L, Sokil MM, Yeh I, Jorgenson E. Prognostic factors and survival in acral lentiginous melanoma. Br J Dermatol. 2017;177(2):428-435. doi:10.1111/bjd.15600

53. Baldwin J, Janitz AE, Erb-Alvarez J, Snider C, Campbell JE. Prevalence and mortality of melanoma in Oklahoma among racial groups, 2000-2008. J Okla State Med Assoc. 2016;109(7-8):311-316.

54. Hu S, Parmet Y, Allen G, et al. Disparity in melanoma. Arch Dermatol. 2009;145(12):1369-1374. doi:10.1001/archdermatol.2009.302

55. Hu S, Soza-Vento RM, Parker DF, Kirsner RS. Comparison of stage at diagnosis of melanoma among Hispanic, black, and white patients in Miami-Dade County, Florida. Arch Dermatol. 2006;142(6):704-708. doi:10.1001/archderm.142.6.704

56. Dick M, Aurit S, Silberstein P. The odds of stage IV melanoma diagnoses based on socioeconomic factors. J Cutan Med Surg. 2019;23(4):421-427. doi:10.1177/1203475419847955

57. Tripathi R, Archibald LK, Mazmudar RS, et al. Racial differences in time to treatment for melanoma. J Am Acad Dermatol. 2020;83(3):854-859. doi:10.1016/j.jaad.2020.03.094

58. Vaidya T, Zubritsky L, Alikhan A, Housholder A. Socioeconomic and geographic barriers to dermatology care in urban and rural US populations. J Am Acad Dermatol. 2018;78(2):406-408. doi:10.1016/j.jaad.2017.07.050

59. Byrd KM, Wilson DC, Hoyler SS, Peck GL. Advanced presentation of melanoma in African Americans. J Am Acad Dermatol. 2004;50(1):21-24. doi:10.1016/S0190-9622(03)02091-7

60. Albrseki D, Sloan SB. Melanoma of the feet: misdiagnosed and misunderstood. Clin Dermatol. 2009;27(6):556-563. doi:10.1016/j.clindermatol.2008.09.014

61. Gorbatenko-Roth K, Prose N, Kundu RV, Patterson S. Assessment of black patients’ perception of their dermatology care. JAMA Dermatol. 2019;155(10):1129-1134. doi:10.1001/jamadermatol.2019.2063

62. Burgin S, Dlova NC, Goldsmith LA. Dermatological education for the 21st century: prioritizing diversity. Br J Dermatol. 2021;184(4):740-741. doi:10.1111/bjd.19663

63. Amuzie AU, Jia JL, Taylor SC, Lester JC. Skin-of-color article representation in dermatology literature 2009-2019: higher citation counts and opportunities for inclusion. J Am Acad Dermatol. 2021;2019-2021. doi:10.1016/j.jaad.2021.03.063

64. Adelekan A, Onyekaba G, Lipoff JB. Skin color in dermatology textbooks: an updated evaluation and analysis. J Am Acad Dermatol. 2021;84(1):194-196. doi:10.1016/j.jaad.2020.04.084

65. Alvarado SM, Feng H. Representation of dark skin images of common dermatologic conditions in educational resources: a cross-sectional analysis. J Am Acad Dermatol. 2021;84(5):1427-1431. doi:10.1016/j.jaad.2020.06.041